Malignant pancreatic carcinoid tumour.
Pancreatic carcinoid tumours are rare, particularly within the paediatric population. The clinical presentation is largely dependent on the functionality of the tumour. Although the tumour is generally slow-growing, surgical resection is still the mainstay of curative treatment. Morbidity is, however, significantly contributed by secretion of excess hormones; in view of this, biotherapy is an important treatment strategy. Octreotide, a somatostatin analogue, has been shown to be successful in both symptomatic control and stability of tumour progression. We report a 12-year-old girl, who presented with hypertensive crisis, and showed good response to a combination of chemotherapy and octreotide.
Zarina
A L
AL
Paediatric Haematology & Oncology Unit, Department of Paediatrics, Faculty of Medicine, Universiti Kebangsaan Malaysia, Jalan Yaacob Latif, Cheras 56000, Kuala Lumpur, Malaysia. zarinaal@mail.hukm.ukm.my
Hamidah
A
A
Zulkifli
S Z
SZ
Zulfiqar
M A
MA
Jamal
R
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001707:Biopsy, Needle; D002276:Carcinoid Tumor / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D002648:Child; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006974:Hypertension, Malignant / Q000175:diagnosis / Q000209:etiology; D007813:Laparotomy / Q000379:methods; D008279:Magnetic Resonance Imaging; D009367:Neoplasm Staging; D015282:Octreotide / Q000008:administration & dosage; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy*; D018570:Risk Assessment; D016896:Treatment Outcome
D015282:Octreotide